Skip to content

Author

M. Voss

We have 2 of 286 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...

N. Zacharias, Eric S Rupe, Xinyue Chen et al. · 0 citations
Open access Sep 2026

Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity

MSK-Tox provides an empirical basis for a new precision safety paradigm for predicting who will be harmed by a therapy on the same principles that guide prediction of therapeutic benefit, and identifies two modes of germline susceptibility to treatment toxicity.

Z. Bakouny, X. Guo, F. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.